Eledon Pharmaceuticals, Inc. 股价、新闻与催化剂

股票表现

股价为何变动

As of Aug 24, 2026, ELDN closed down 1.16% at $3.41. No new same-company headline was identified in the current news window.

公司概览

未来催化剂

• 2026年底启动全球特戈普鲁巴3期肾移植研究。

近期新闻

1. 01
   2026-08-13 20:05 EST

   Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

2. 02
   2026-06-22 11:00 EST

   Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

3. 03
   2026-06-08 11:00 EST

   Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

4. 04
   2026-06-04 20:31 EST

   Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

5. 05
   2026-05-20 20:05 EST

   Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

相似股票

商业成熟度、治疗领域或催化剂模式相近的同行公司。